Pα+ is the insider’s guide to the business, policy and science of psychedelics.

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

psychedelicalpha.com/join

“Evidence-based training and participation in a consultation community are two important ways to encourage the steady growth of psychedelic medicine, and these are resources that we didn’t really have in the early days of Ketamine Infusion Therapy (KIT), in part because we had ines providing the treatment.”

L. Alison McInnes, spoke with us for the seventh Issue of The Psychedelic Practitioner, which focuses on psychedelic preparedness (systems).

Read now on our website: psychedelicalpha.com/news/the-psych…

Across Europe, psychedelics are entering a new chapter, one defined less by proof-of-concept studies and more by implementation and early-access schemes that don’t rely on conventional drug approvals.

On 8–9 October, more than 270 clinicians, researchers, policymakers, advocates ic gathered at the National Library of Estonia in Tallinn for TAIP 2026, Estonia’s first international scientific conference on psychedelic-assisted therapy. There, they discussed various innovative models of regulated psychedelics access. 

Ryan Khan was on-site for Psychedelic Alpha. Today, we share his 5,000+ word Dispatch.

Read more on our website: psychedelicalpha.com/news/before-th…

Since President Trump's psychedelics-focused Executive Order in April, a slew of federal agencies and departments have engaged in related activities: from funding psychedelic research through to public hearings and requests for information.

“Conversion of codes from Category III to Category I requires their usage and reporting for relevant services. There is also the consideration of the AMA’s CPT Editorial Meeting calendar. It may take about 12-18 months for this conversion.”

Steve Levine, spoke with us for the ychedelic Practitioner, which focuses on psychedelic preparedness (systems).

Read now on our website: psychedelicalpha.com/news/the-psych…

“It’s going to be slower going than our veteran population would like... So, as far as numbers of patients we’ll be able to treat, I think to manage expectations, it’ll be a challenge in the first year to treat four digits worth of patients.”

Andrew Gradison, Senior Advisor, rans Affairs, speaking at The Psychedelic Healthcare Forum

Ten VA Sites, REMS and Ibogaine’s “Uphill Battle”: Feds Weigh In on Psychedelic Access

At the Psychedelic Healthcare Forum, which took place in New York City last Thursday and was co-hosted by Psychedelic Alpha, a panel of federal officials participated in a discussion moderated th Care Editor Erin Schumaker.

Read more on our website: psychedelicalpha.com/news/ten-va-si…

The Institute for Clinical and Economic Review (ICER), an independent organisation that reviews healthcare interventions with a mind to cost-effectiveness, today announced that it will assess the comparative clinical effectiveness and value of Compass Pathways’ psilocybin for ression. 

This will be the second psychedelic therapy that the organisation has assessed. In June 2024, ICER reviewed MDMA for PTSD, concluding that the available evidence was insufficient to determine benefit due to methodological issues.

Poacher Turned Gamekeeper: HHS’ Matt Zorn on Ibogaine, Right to Try and the Psychedelics Executive Order

At The Psychedelic Healthcare Forum that we co-hosted last Thursday in New York, our Editor Josh Hardman sat down with Matt Zorn, Deputy General Counsel at the U.S. d Human Services, for a wide-ranging discussion. It was the first in-depth one-to-one interview that Zorn has participated in since taking the role. 

Read the full interview on our website: psychedelicalpha.com/news/poacher-t…

“If psychedelic treatments are offered predominantly in fancy clinics in large cities, or if insurers cover the drug but not the staff time, monitoring, and the preparation and integration sessions (and any other follow-up visits), then in practice psychedelic treatments will be e who are well resourced.”

Marcus Hughes, spoke with us for the seventh Issue of The Psychedelic Practitioner, which focuses on psychedelic preparedness (systems).

Read now on our website: psychedelicalpha.com/news/the-psych…

“The first few years of Spravato were a bit of a bust because of logistics. Let’s not repeat that.”

Carlene MacMillan, spoke with us for the seventh Issue of The Psychedelic Practitioner, which focuses on psychedelic preparedness (systems).

Read now on our website: psychedelicalpha.com/news/the-psych…

Early Healthcare Forum Takeaways, FDA’s Ibogaine Blueprint, and Compass Talks Pricing

In this episode of The Psychedelic News Feed podcast, Psychedelic Alpha’s editor Josh Hardman runs through the last two weeks in the psychedelics field, including these stories:
• Early Notes althcare Forum
• FDA Floats an Ibogaine Trial Design, Asks Field for Input
• Compass Talks Pricing, Label and a Slow Launch
• New Mexico Nears Medical Psilocybin Launch
• Six More Potential Psychedelic Brand Names

Listen on our website or on your favourite podcast app: psychedelicalpha.com/news/podcast-e…

Opted for ‘the drowse’ for the trip home from The Psychedelic Healthcare Forum @Psyched_Alpha and Horizons

The cocktail will have to wait…

On Thursday, Psychedelic Alpha co-hosted The Psychedelic Healthcare Forum at the New York Academy of Medicine.

There, drug developers, regulators, investors, care delivery experts and others came together to discuss the potential rollout of psychedelic therapies in the U.S. e to follow.

“The way forward, without reducing therapy, is group-based treatment and eventually group dosing. It’s a different model, but with expert facilitation it could expand access dramatically and even deepen quality.”

Joe Starke, spoke with us for the seventh Issue of The Psychedelic uses on psychedelic preparedness (systems).

Read now on our website: psychedelicalpha.com/news/the-psych…

Where is our Chief Medical Officer, Dan Karlin this week? Dan attended Psychedelic Alpha’s Psychedelic Healthcare Forum and participated in a panel alongside industry leaders about the new era of psychedelic drug research and development.

The forum brought together a community space, from administrators at the U.S. Department of Veterans Affairs and Health and Human Services to psychedelic industry investors and professional education experts.

#DefiniumTherapeutics #HealthcareInnovation #MentalHealth #PsychedelicMedicine #Neuroscience

Lilly wants to study and improve the psychedelic ibogaine, its neuro leader says

@ky_lahucik and @maxonwifi for Endpoints.

endpoints.news/lilly-interest…

“People can have very high expectations of these treatments, which can be evident from the first contact with the clinic, which is where we begin the preparation and informed consent process. It can take time to ensure people are made fully aware, ethically, about the potential Monica Schweickle

Read now on our website: psychedelicalpha.com/news/the-psych…

“I do think it is important to remember that, while setting is of course important, we can still get good results for patients in a less-than-ideal ambiance. To me, attentive and caring staff are the most important elements of setting and if we are to scale psychedelic treatments with less posh spaces.” - L. Alison McInnes

Read now on our website: psychedelicalpha.com/news/the-psych…

In this Issue, we explore systems preparedness: how practitioners can prepare their infrastructure, physical space, staffing, compliance, and reimbursement processes to safely and effectively deliver psychedelic therapies as potential regulatory approvals draw closer.

Issue 7 rom L. Alison McInnes, Joe Starke, Monica Schweickle, Amanda Gow, Ryan Wakim, Myriam Barthes, Carlene MacMillan, Marcus Hughes, and Steve Levine.

Read now on our website: psychedelicalpha.com/news/the-psych…

Self-Reported Benefits and Harms Differ by Psychedelic

According to analysis of survey data from the 2025 National Survey Investigating Hallucinogenic Trends (NSIHT), self-attributed adverse outcomes were most often associated with respondents who reported using ibogaine or rious limitations to the study, including differences across those who use one drug versus another, as well as the potential for co-substance use, and so on. 

Read more on our website: psychedelicalpha.com/news/p%ce%b1-p…